{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003052","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.762071+00:00","generated_at":"2026-06-06T09:30:38.570914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mesa Labs Q3 revenue down 1.5%; operating loss of $67K; core organic revenue declines 9%","bullets":["Revenue $53.5M, down 1.5% YoY; core organic revenue declined 9%.","Operating loss of $67K vs income $3.2M prior year; net income $2.1M up 369% on unusual items.","Non-GAAP adjusted operating income excl. unusual items $12.0M, down 6.8% YoY but up 7.3% sequentially.","Clinical Genomics down 19% on China anti-corruption; Biopharm capital constrained but consumables +16.5%.","Calibration Solutions revenue +12.9%, gross margin +600 bps; GKE acquisition added $3.8M revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003052","json":"https://secwatch.observer/filing/0001437749-24-003052.json","markdown":"https://secwatch.observer/filing/0001437749-24-003052.md","text":"https://secwatch.observer/filing/0001437749-24-003052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774924003052/0001437749-24-003052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774924003052/mlab20240202_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:30:38.570914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"595d9e384c182601ab2c081f5b14c8d5d57a39f9","claim":"MESA LABORATORIES INC /CO/ reported third fiscal quarter ended December 31, 2023 results: revenue $53,473, net income $2,116, EPS $0.39 per diluted share of common stock.","evidence_excerpt":"● Non-GAAP adjusted operating income excluding unusual items as a percentage of revenues increased sequentially to 22.4% Executive Commentary (amounts in thousands) “Revenues of $53,473 for the quarter decreased 1.5% as compared to the third quarter of fiscal year 2023 (“3Q23”), due primarily to a 9.0% core organic revenues (“core organic”) decrease which was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774924003052/0001437749-24-003052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third fiscal quarter ended December 31, 2023"},{"label":"Revenue","value":"$53,473"},{"label":"Net income","value":"$2,116"},{"label":"EPS","value":"$0.39 per diluted share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}